PVC Clinical Trials & Post-Marketing Surveillance 2 — Questions and Answers
Question 1: Which regulatory framework requires sponsors to submit Individual Case Safety Reports (ICSRs) for serious unexpected adverse events during clinical trials?
- ICH E6 Good Clinical Practice
- ICH E2A Clinical Safety Data Management (Correct answer)
- ICH E3 Clinical Study Reports
- ICH E8 General Considerations for Clinical Trials
Correct answer: ICH E2A Clinical Safety Data Management
ICH E2A defines expedited reporting requirements for serious unexpected adverse drug reactions occurring during clinical development.
Question 2: A Phase II oncology trial observes a cluster of Grade 3 hepatotoxicity events. What is the FIRST action the Data Safety Monitoring Board (DSMB) should take?
- Immediately terminate the trial
- Conduct an unblinded review of the safety data (Correct answer)
- Notify the FDA within 7 days
- Reduce the dose for all enrolled patients
Correct answer: Conduct an unblinded review of the safety data
The DSMB's primary role is to review unblinded safety data to determine whether the observed events warrant trial modification or termination.
Question 3: In post-marketing surveillance, a Periodic Safety Update Report (PSUR) is submitted at what frequency for a newly approved drug in its first two years?
- Every 6 months (Correct answer)
- Annually
- Every 2 years
- Only when triggered by a safety signal
Correct answer: Every 6 months
ICH E2C(R2) requires PSURs every 6 months for the first 2 years post-approval to enable close monitoring of new medicines.
Question 4: Which type of post-marketing study is specifically mandated by regulators to fulfill a condition of approval and must be completed within an agreed timeframe?
- Phase IV investigator-initiated study
- Post-Authorization Safety Study (PASS) (Correct answer)
- Registry study
- Spontaneous reporting program
Correct answer: Post-Authorization Safety Study (PASS)
A PASS is a regulatory commitment study designed to evaluate safety concerns identified at the time of approval.
Question 5: A marketed drug's spontaneous reporting rate for agranulocytosis suddenly doubles over three months. Under the FDA sentinel system, what is the most appropriate next step?
- Issue an immediate market withdrawal
- Conduct a disproportionality analysis using ROR or PRR (Correct answer)
- Update the label within 30 days
- Request a randomized controlled trial
Correct answer: Conduct a disproportionality analysis using ROR or PRR
Disproportionality analysis using Reporting Odds Ratio (ROR) or Proportional Reporting Ratio (PRR) is the standard signal detection method for spontaneous report databases.
Question 6: During a blinded clinical trial, an investigator learns that a patient experienced a suspected unexpected serious adverse reaction (SUSAR). How should unblinding be handled?
- The trial should remain fully blinded and the event coded as unknown treatment
- The sponsor's safety team may unblind solely for expedited reporting purposes (Correct answer)
- The investigator must unblind immediately and inform all other site personnel
- Unblinding is prohibited until the trial concludes
Correct answer: The sponsor's safety team may unblind solely for expedited reporting purposes
Selective unblinding for the safety team allows proper SUSAR assessment and expedited reporting while preserving trial integrity for all other personnel.
Question 7: Which post-marketing pharmacovigilance tool uses insurance claims and electronic health records to detect drug safety signals in large real-world populations?
- Yellow Card Scheme
- FDA MedWatch
- FDA Sentinel System (Correct answer)
- WHO Uppsala Monitoring Centre VigiBase
Correct answer: FDA Sentinel System
The FDA Sentinel System actively queries healthcare databases including claims and EHR data to conduct large-scale epidemiological analyses.
PVC Clinical Trials & Post-Marketing Surveillance 2
Which regulatory framework requires sponsors to submit Individual Case Safety Reports (ICSRs) for serious unexpected adverse events during clinical trials?